BRAF and thyroid cancer: The latter is reported to be overexpressed in PTC clinical samples [87] and mediates the resistance to mitogen-activated protein kinase (MAPK) inhibitors in BRAF-mutant thyroid cancer cell lines [88], implying that ERBB2 could drastically affect the thyroid tumorigenesis.